The effect of a new adrenergic beta 2 -receptor-stimulating agent (rimiterol, R798) in patients with chronic obstructive lung disease.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000336:Aerosols; D000605:Amino Alcohols / Q000494:pharmacology / Q000627:therapeutic use*; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002396:Catechols / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007231:Infant, Newborn; D007545:Isoproterenol / Q000494:pharmacology / Q000627:therapeutic use*; D008171:Lung Diseases / Q000188:drug therapy*; D000432:Methanol / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D012119:Respiration / Q000187:drug effects*; D013147:Spirometry; D013268:Stimulation, Chemical; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D000336:Aerosols; D000605:Amino Alcohols; D001993:Bronchodilator Agents; D002396:Catechols; D010880:Piperidines; D010919:Placebos; C084590:rimiterol; D007545:Isoproterenol; D000432:Methanol